31 results
SC 14D9/A
EX-99
PNT
POINT Biopharma Global Inc.
18 Dec 23
Tender offer solicitation (amended)
8:14am
. The American Cancer Society estimates that in 2023, almost 288,300 new cases of prostate cancer will be diagnosed, and about 34,700 men will die … with the SEC for free on the SEC’s website at www.sec.gov.
American Cancer Society. Facts & Figures 2023. American Cancer Society. Atlanta, GA. 2023
SC TO-T
EX-99
PNT
POINT Biopharma Global Inc.
13 Oct 23
Third party tender offer statement
6:52am
Academy of Medicine, the National Academy of Sciences, the American College of Physicians, the Association of American Physicians, the American Society
8-K
EX-99.1
PNT
POINT Biopharma Global Inc.
14 Aug 23
POINT Biopharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights
7:21am
study to be available in the first half of 2024.
In June 2023, a Trial-in-Progress poster for FRONTIER was presented at the 2023 American Society … .
Later in June 2023, we published and presented preclinical data at the 2023 Annual Meeting of the Society of Nuclear Medicine & Molecular Imaging
ARS
2022 FY
PNT
POINT Biopharma Global Inc.
1 May 23
Annual report to shareholders
1:52pm
at-risk groups. The American Cancer Society estimates that there will be approximately-288,300 new prostate cancer cases and over 34,700 deaths due … , there was a prevalence of 187,000 people with NETs in the U.S. in 2016 and an estimate of 33,000 newly diagnosed cases. The American Society of Clinical Oncology
424B5
rufffrs
14 Sep 22
Prospectus supplement for primary offering
4:12pm
424B5
cuqeb
13 Sep 22
Prospectus supplement for primary offering
5:19pm
8-K
EX-99.2
od9ek4
12 Sep 22
POINT Biopharma Provides Updated Efficacy and Safety Data from the Lead-In Cohort of the Phase 3 SPLASH Trial in mCRPC at ESMO Congress 2022
7:54am
8-K
qnwoi19dp3snhc32
12 Sep 22
POINT Biopharma Provides Updated Efficacy and Safety Data from the Lead-In Cohort of the Phase 3 SPLASH Trial in mCRPC at ESMO Congress 2022
7:54am
8-K
e671mcu stj08
6 Sep 22
POINT Biopharma Announces Poster Presentation at ESMO Congress 2022 Containing Efficacy & Safety Data from Lead-In Cohort of Phase 3 SPLASH Trial
8:11am
S-3
382sct54bmh
1 Jul 22
Shelf registration
4:13pm
424B3
p8tnd9ntjma663bnzly
13 May 22
Prospectus supplement
8:18am
424B3
ca46z1e
31 Mar 22
Prospectus supplement
11:42am
POS AM
43lyjhhvapwjfkq yb3
25 Mar 22
Prospectus update (post-effective amendment)
8:41am
424B3
efumqqt fgvv
12 Nov 21
Prospectus supplement
8:41am
424B3
kfj9ygsmjt0k5ww3d4l
13 Aug 21
Prospectus supplement
5:25pm